Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction

被引：1

作者：

Wells, Quinn S. ^{[1
,2
]}

Farber-Eger, Eric ^{[1
,2
]}

Lipworth, Loren ^{[2
,3
]}

Dluzniewski, Paul ^{[4
]}

Dent, Ricardo ^{[4
]}

Umeijiego, John ^{[4
]}

Cohen, Sarah S. ^{[3
,5
]}

机构：

[1] Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Med Ctr, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Vanderbilt Translat & Clin Cardiovasc Res Ctr VTR, Nashville, TN USA

[3] Vanderbilt Univ, Dept Med, Div Epidemiol, Med Ctr, Nashville, TN 37235 USA

[4] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA

[5] Toxstrategies Inc, Epidstrategies, Cary, NC 27511 USA

来源：

CLINICAL EPIDEMIOLOGY | 2022年 / 14卷

关键词：

heart failure; reduced ejection fraction; real-world evidence; electronic health record; RANDOMIZED INTERVENTION TRIAL; CIBIS-II; MORTALITY; ENALAPRIL; SURVIVAL; METOPROLOL; MORBIDITY; OUTCOMES;

D O I：

10.2147/CLEP.S341919

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

li li li Conclusion: Approximately 40% of RW HFrEF patients met criteria for the GALACTICHF trial. While findings of ongoing clinical trials may be directly generalizable to this sizable proportion of patients, future trials should examine whether the majority of patients with lower prevalence of comorbidities and rate of HF hospitalization could benefit from emerging HF treatments.

引用

页码：39 / 49

页数：11

共 50 条

[31] Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
Di Lenarda, Andrea
Di Gesaro, Gabriele
Sarullo, Filippo Maria
Miani, Daniela
Driussi, Mauro
Correale, Michele
Bilato, Claudio
Passantino, Andrea
Carluccio, Erberto
Villani, Alessandra
degli Esposti, Luca
d'Agostino, Chiara
Peruzzi, Elena
Poli, Simone
Iacoviello, Massimo
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
[32] Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction Rationale and Design of the LIFE Trial
Mann, Douglas L.
Greene, Stephen J.
Givertz, Michael M.
Vader, Justin M.
Starling, Randall C.
Ambrosy, Andrew P.
Shah, Palak
McNulty, Steven E.
Mahr, Claudius
Gupta, Divya
Redfield, Margaret M.
Lala, Anuradha
Lewis, Gregory D.
Mohammed, Selma F.
Gilotra, Nisha A.
DeVore, Adam D.
Gorodeski, Eiran Z.
Desvigne-Nickens, Patrice
Hernandez, Adrian F.
Braunwald, Eugene
JACC-HEART FAILURE, 2020, 8 (10) : 789 - 799
[33] The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings
Mazza, Alberto
Townsend, Danyelle M.
Torin, Gioia
Schiavon, Laura
Camerotto, Alessandro
Rigatelli, Gianluca
Cuppini, Stefano
Minuz, Pietro
Rubello, Domenico
BIOMEDICINE & PHARMACOTHERAPY, 2020, 130
[34] Aldosterone Antagonists and Outcomes in Real-World Older Patients With Heart Failure and Preserved Ejection Fraction
Patel, Kanan
Fonarow, Gregg C.
Kitzman, Dalane W.
Aban, Inmaculada B.
Love, Thomas E.
Allman, Richard M.
Gheorghiade, Mihai
Ahmed, Ali
JACC-HEART FAILURE, 2013, 1 (01) : 40 - 47
[35] Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry
de Frutos, Fernando
Mirabet, Sonia
Ortega-Paz, Luis
Buera, Irene
Darnes, Sara
Farre, Nuria
Andres, Bernardo
Adelino, Raquel
Bascompte, Ramon
Perez-Rodon, Jordi
Aparicio, Xavier
Sutil-Vega, Mario
Soto, Adriana
Faraudo, Mercedes
Cainzos-Achirica, Miguel
Manito, Nicolas
ESC HEART FAILURE, 2020, 7 (01): : 26 - 36
[36] Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
Ganesananthan, Sashiananthan
Shah, Nisar
Shah, Parin
Elsayed, Hossam
Phillips, Julie
Parkes, Ann
Morgan, Angharad
Yousef, Zaheer
OPEN HEART, 2020, 7 (02):
[37] A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms
Farzin Beygui
Manuel Anguita
Ulrich Tebbe
Josep Comin-Colet
Michel Galinier
Peter Bramlage
Eva Turgonyi
Katharina Lins
Lynda Imekraz
Trinidad de Frutos
Michael Böhm
Heart Failure Reviews, 2015, 20 : 545 - 552
[38] The Importance of Heart Rate in Heart Failure and Reduced Ejection Fraction
Prasun, Marilyn A.
Albert, Nancy M.
JOURNAL OF CARDIOVASCULAR NURSING, 2018, 33 (05) : 453 - 459
[39] Exercise oscillatory breathing in heart failure with reduced ejection fraction: clinical implication
Goulart, Cassia da Luz
Agostoni, Piergiuseppe
Salvioni, Elisabetta
Kaminsky, Leonard A.
Myers, Jon
Arena, Ross
Borghi-Silva, Audrey
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (12) : 1692 - 1698
[40] The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction
Nichols, Gregory A.
Qiao, Qing
Deruaz-Luyet, Anouk
Kraus, Bettina J.
IJC HEART & VASCULATURE, 2023, 47

← 1 2 3 4 5 →